logo-loader
viewModerna Therapeutics Inc

Moderna announces positive interim data on Covid-19 vaccine candidate

The next set of trials, potentially scheduled for July, will be the final stage before submitting the candidate to the authorities

Moderna Therapeutics Inc - Moderna announces positive interim data on Covid-19 vaccine candidate

Moderna Inc (NASDAQ:MRNA) has announced positive interim clinical data of its vaccine candidate against Covid-19.

The US biotech firm said the new data reinforces the belief that its mRNA-based vaccine could be effective in preventing infections, without serious side effects.

READ: Avacta says partner Moderna takes collaboration to next level

The third and final phase of trials is pencilled in for July, followed by biologic licence application to the US Food and Drug Administration if successful.

“We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2,” said chief executive Stéphane Bancel.

Shares climbed 30% to US$86.79 at the opening bell on Monday.

Quick facts: Moderna Therapeutics Inc

Price: 69 USD

NASDAQ:MRNA
Market: NASDAQ
Market Cap: $25.61 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan's Cathal Friel on its £12mln raise to accelerate coronavirus...

Open Orphan PLC's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing they've raised approximately £12mln to ramp up its coronavirus (COVID-19) antiviral testing. Friel says the fundraise has brought many new leading blue-chip institutional shareholders to their...

3 days, 14 hours ago

2 min read